New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
08:08 EDTMNTAMomenta Pharma stills sees 2013 operating cash use about $90M
Momenta confirmed its guidance, previously provided in November, for total operating expenses, excluding stock-based compensation and net of collaborative revenues, of approximately $30M per quarter in 2013. For 2013, Momenta is projecting that its net cash usage will average approximately $20M-$24M per quarter for a total operating cash usage of approximately $90M.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
08:10 EDTMNTAMomenta price target raised to $24 from $16 at Leerink
Subscribe for More Information
08:00 EDTMNTATeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
07:46 EDTMNTAMomenta price target raised to $25 from $15 at Brean Capital
Brean Capital raised its price target on Momenta to $25 from $15 following yesterday's announcement of the approval of generic Copaxone. Brean Capital reiterated its Buy rating on Momenta shares.
April 16, 2015
15:40 EDTMNTAGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylanís (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
12:37 EDTMNTAMomenta confirms Glatopa approval, to receive $10M payment
Subscribe for More Information
12:35 EDTMNTASandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
12:35 EDTMNTAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
12:29 EDTMNTAMomenta jumps after FDA denies Teva petition to block generic Copaxone
April 8, 2015
11:52 EDTMNTAMomenta downgraded to Neutral from Buy at UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use